El juicio del hambre | GLP-1, Ozempic y la nueva ciencia de la obesidad

Algunas de las referencias más relevantes que utilicé para realizar este video: Drucker, D. J. (2024). Advances in oral peptide therapeutics. Nature Reviews Drug Discovery. Gerstein, H. C., Colhoun, H. M., Dagenais, G. R., Diaz, R., Lakshmanan, M., Pais, P., Probstfield, J., Riesmeyer, J. S., Riddle, M. C., Ryden, L., Xavier, D., & others. (2019). Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND). The Lancet, 394(10193), 121–130. https://doi.org/10.1016/S0140-6736(19... Hayes, M. R., & Schmidt, H. D. (2016). GLP-1 influences food reward. Physiology & Behavior, 162, 66–75. https://doi.org/10.1016/j.physbeh.201... Jastreboff, A. M., et al., (2022). Tirzepatide once weekly for the treatment of obesity. The New England Journal of Medicine, 387(3), 205–216. https://doi.org/10.1056/NEJMoa2206038 Knudsen, L. B., & Lau, J. (2019). The discovery and development of liraglutide and semaglutide. Frontiers in Endocrinology, 10, 155. https://doi.org/10.3389/fendo.2019.00155 Lincoff, A. M., et al., (2023). Semaglutide and cardiovascular outcomes in obesity without diabetes. The New England Journal of Medicine, 389(24), 2221–2232. https://doi.org/10.1056/NEJMoa2307563 Loomba, R., Neutel, J., Mohseni, R., Bernard, D., Severance, R., Dao, M., & others. (2024). Semaglutide in metabolic dysfunction-associated steatohepatitis. The New England Journal of Medicine. Lundgren, J. R., et al., (2021). Healthy weight loss maintenance with exercise, GLP-1 receptor agonist, or both combined followed by one year without treatment: A randomised placebo-controlled trial. Nature Medicine, 27(10), 1834–1844. https://doi.org/10.1038/s41591-021-01... Mann, J. F. E., et al., (2018). Liraglutide and renal outcomes in type 2 diabetes. Circulation, 138(25), 2908–2918. https://doi.org/10.1161/CIRCULATIONAH... Marso, S. P., et al., (2016). Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. The New England Journal of Medicine, 375(19), 1834–1844. https://doi.org/10.1056/NEJMoa1607141 Marso, S. P., et al., (2016). Liraglutide and cardiovascular outcomes in type 2 diabetes. The New England Journal of Medicine, 375(4), 311–322. https://doi.org/10.1056/NEJMoa1603827 Müller, T. D., et al., (2019). Glucagon-like peptide 1 (GLP-1). Molecular Metabolism, 30, 72–130. https://doi.org/10.1016/j.molmet.2019... Nauck, M. A., & Meier, J. J. (2018). Incretin hormones: Their role in health and disease. Diabetes, Obesity and Metabolism, 20(Suppl. 1), 5–21. https://doi.org/10.1111/dom.13129 Newsome, et al., (2021). A placebo-controlled trial of subcutaneous semaglutide in nonalcoholic steatohepatitis. The New England Journal of Medicine, 384(12), 1113–1124. https://doi.org/10.1056/NEJMoa2028395 Wilding, J. P. H., et al., (2021). Once-weekly semaglutide in adults with overweight or obesity. The New England Journal of Medicine, 384(11), 989–1002. https://doi.org/10.1056/NEJMoa2032183 American Diabetes Association. (2026). Standards of care in diabetes—2026. Diabetes Care, 49(Supplement 1). American Association of Clinical Endocrinology. (2023). Clinical practice guideline for obesity and diabetes management.